Previous 10 | Next 10 |
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also...
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be presenting and participating in one-on-one meetings at the H.C. Wainwright 24 ...
Today, we take our first look at the rebranded/refocused Biora Therapeutics in 2022. When we last looked at this company, it was still transitioning from being a genetic testing company to being a developmental drug company. How is the transformation working out to date? An ...
The following slide deck was published by Biora Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Biora Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Biora Therapeutics, Inc. (BIOR) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Adi Mohanty – Chief Executive Officer Eric d’Esparbes – Chief Financial Officer Conference Call Participants Julian Harri...
Biora Therapeutics press release ( NASDAQ: BIOR ): Q2 GAAP EPS of $0.03 beats by $0.15 . Revenue of $0.9M (+95.7% Y/Y). Shares -1.9% . For further details see: Biora Therapeutics GAAP EPS of $0.03 beats by $0.15, revenue of $0.9M
Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients Successfully completed PM-611 human study for its targeted therapeutics platform in healthy volunteers showing pr...
Major earnings expected after the bell on Monday include: Tencent Music Entertainment Group ( TME ) Planet 13 Holding ( OTCQX:PLNHF ) XpresSpa Group ( XSPA ) T2 Biosystems ( TTOO ) IonQ( IONQ ) For further details see: Notable earnings aft...
Biora Therapeutics ( NASDAQ: BIOR ), a biotech focused on oral biotherapeutics, surged ~30% on Wednesday to record the highest intraday gain since November after the company announced promising topline data from a study for its targeted therapeutics platform. The recen...
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...